• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    1/31/24 4:31:06 PM ET
    $ALGN
    $ATPC
    $ENSC
    $KPTI
    Industrial Specialties
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ALGN alert in real time by email

    Gainers

    • TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 17.2% to $0.81 during Wednesday's after-market session.
    • Align Tech (NASDAQ:ALGN) shares increased by 13.29% to $302.86. The company's market cap stands at $23.1 billion. The company's, Q4 earnings came out today.
    • Revelation Biosciences (NASDAQ:REVB) shares rose 12.39% to $9.7. The company's market cap stands at $2.0 million.
    • Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 11.91% to $27.99. The market value of their outstanding shares is at $1.6 billion.
    • Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 7.92% to $0.81. The market value of their outstanding shares is at $92.7 million.
    • PaxMedica (NASDAQ:PXMD) stock rose 7.53% to $0.55. The company's market cap stands at $2.5 million.

    Losers

    • Pieris Pharmaceuticals (NASDAQ:PIRS) stock decreased by 11.7% to $0.16 during Wednesday's after-market session. The market value of their outstanding shares is at $16.1 million.
    • Ocean Biomedical (NASDAQ:OCEA) shares decreased by 10.16% to $0.51. The company's market cap stands at $17.4 million.
    • MAIA Biotechnology (AMEX:MAIA) shares decreased by 8.01% to $1.38. The company's market cap stands at $23.4 million.
    • Ensysce Biosciences (NASDAQ:ENSC) shares decreased by 6.84% to $1.5. The company's market cap stands at $4.7 million.
    • Agape ATP (NASDAQ:ATPC) stock decreased by 6.26% to $0.61. The market value of their outstanding shares is at $46.8 million.
    • OneMedNet (NASDAQ:ONMD) stock declined by 5.3% to $1.79. The market value of their outstanding shares is at $57.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGN
    $ATPC
    $ENSC
    $KPTI

    CompanyDatePrice TargetRatingAnalyst
    Align Technology Inc.
    $ALGN
    3/17/2026$200.00Equal Weight → Overweight
    Barclays
    Karyopharm Therapeutics Inc.
    $KPTI
    3/10/2026$28.00Buy
    Rodman & Renshaw
    Align Technology Inc.
    $ALGN
    2/9/2026$200.00Hold → Buy
    HSBC Securities
    Karyopharm Therapeutics Inc.
    $KPTI
    2/5/2026Overweight
    Cantor Fitzgerald
    Align Technology Inc.
    $ALGN
    12/9/2025$170.00Equal Weight
    Barclays
    Karyopharm Therapeutics Inc.
    $KPTI
    10/13/2025$15.00Neutral → Buy
    H.C. Wainwright
    Align Technology Inc.
    $ALGN
    10/10/2025$140.00Buy → Hold
    Jefferies
    Protagonist Therapeutics Inc.
    $PTGX
    9/17/2025$72.00Overweight
    Barclays
    More analyst ratings

    $ALGN
    $ATPC
    $ENSC
    $KPTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Stan bought $9,959 worth of shares (2,700 units at $3.69) and received a gift of 20,000 shares (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    1/12/26 8:44:30 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $69,999 worth of shares (57,189 units at $1.22) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:18:50 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chaouki Steven M bought $49,999 worth of shares (40,849 units at $1.22), increasing direct ownership by 37% to 151,873 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/23/25 8:16:48 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $ATPC
    $ENSC
    $KPTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Align Technology to Announce First Quarter 2026 Results on April 29, 2026

    Align Technology, Inc. (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report first quarter 2026 financial results on Wednesday, April 29, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com. Following the press release, Align will host a conference call to discuss its financial results. The conference call will be

    4/1/26 4:23:00 PM ET
    $ALGN
    Industrial Specialties
    Health Care

    OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI

    MINNEAPOLIS, April 01, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a collaboration with OneMedNet Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet's iRWD™ platform— powered by Palantir (PLTR) Foundry— providing it access to U.S. real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and re

    4/1/26 8:55:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

    New York, March 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE:MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology's business, recent updates, management commentary, financial results, valuation, and risks. The full update note is available below. MAIA Biotechnology March 2026 Update Note Highlights from the note include:                                               FY 2025 Financial

    3/27/26 8:00:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $ATPC
    $ENSC
    $KPTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Align Tech upgraded by Barclays with a new price target

    Barclays upgraded Align Tech from Equal Weight to Overweight and set a new price target of $200.00

    3/17/26 7:53:01 AM ET
    $ALGN
    Industrial Specialties
    Health Care

    Rodman & Renshaw initiated coverage on Karyopharm Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $28.00

    3/10/26 8:41:07 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Align Tech upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Align Tech from Hold to Buy and set a new price target of $200.00

    2/9/26 6:58:22 AM ET
    $ALGN
    Industrial Specialties
    Health Care

    $ALGN
    $ATPC
    $ENSC
    $KPTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chaouki Steven M

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    4/2/26 4:56:47 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Guerrero Ramiro

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    4/2/26 4:55:27 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Louie Ngar Yee

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    4/2/26 4:53:36 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $ATPC
    $ENSC
    $KPTI
    SEC Filings

    View All

    SEC Form 8-K filed by Ensysce Biosciences Inc.

    8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

    4/3/26 4:14:43 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Karyopharm Therapeutics Inc.

    SCHEDULE 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    4/2/26 4:47:09 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Karyopharm Therapeutics Inc.

    SCHEDULE 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    4/2/26 4:26:26 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $ATPC
    $ENSC
    $KPTI
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

    Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

    6/24/25 8:15:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $ATPC
    $ENSC
    $KPTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

    SC 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

    12/17/24 5:42:35 PM ET
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Ensysce Biosciences Inc.

    SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

    11/14/24 5:52:56 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $ATPC
    $ENSC
    $KPTI
    Financials

    Live finance-specific insights

    View All

    Align Technology to Announce First Quarter 2026 Results on April 29, 2026

    Align Technology, Inc. (NASDAQ:ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report first quarter 2026 financial results on Wednesday, April 29, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com. Following the press release, Align will host a conference call to discuss its financial results. The conference call will be

    4/1/26 4:23:00 PM ET
    $ALGN
    Industrial Specialties
    Health Care

    Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

    – While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS – – SENTRY Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib –– Promising Overall Survival Signal with >50% Reduction of Risk of Death versus Ruxolitinib –– Evidence of Potential Disease Modification with More Patients Achieving ≥20% Reductions in VAF as Early as Week 24 versus Ruxolitinib –– No New Safety Signals Identified –– Karyopharm will Meet with the FDA to Discuss the Totality of the Data and Potential sNDA Filing – – Conference Call Scheduled for Today at 8:00 a.m. ET –NEWTON, Mass., M

    3/24/26 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

    – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Total Revenue was $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $115 Million for Full Year 2025 – – Company Provides Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Feb. 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapie

    2/12/26 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care